The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up
about
Integrating Geriatric Assessment into Decision-Making after Prostatectomy: Adjuvant Radiotherapy, Salvage Radiotherapy, or None?Management of patients with biochemical recurrence after local therapy for prostate cancerCombining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapyLoss of tumor suppressor mir-203 mediates overexpression of LIM and SH3 Protein 1 (LASP1) in high-risk prostate cancer thereby increasing cell proliferation and migration.Error rates in a clinical data repository: lessons from the transition to electronic data transfer--a descriptive study.Analysis of the correlation between endorectal MRI response to neoadjuvant chemotherapy and biochemical recurrence in patients with high-risk localized prostate cancer.Copy number alteration burden predicts prostate cancer relapseAdjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trialsCancer of the Prostate Risk Assessment (CAPRA) Preoperative Score Versus Postoperative Score (CAPRA-S): ability to predict cancer progression and decision-making regarding adjuvant therapy after radical prostatectomy.Overdetection of recurrence after radical prostatectomy: estimates based on patient and tumor characteristicsPhytotherapeutic interventions in the management of biochemically recurrent prostate cancer: a systematic review of randomised trials.Change in PSA velocity is a predictor of overall survival in men with biochemically-recurrent prostate cancer treated with nonhormonal agents: combined analysis of four phase-2 trials.A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomyDisease-specific outcomes of radical prostatectomies in Northern Norway; a case for the impact of perineural infiltration and postoperative PSA-doubling time.Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up studyLenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer.Changes in PSA kinetics predict metastasis- free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents: combined analysis of 4 phase II trialsPrognostic Factors for Prostate Cancer Endpoints Following Biochemical Failure: A Review of the Literature.Tumor Volume and Clinical Failure in High-Risk Prostate Cancer Patients Treated With Radical Prostatectomy.Does salvage radiation therapy change the biology of recurrent prostate cancer based on PSA doubling times? Results from the SEARCH database.Auger Radiopharmaceutical Therapy Targeting Prostate-Specific Membrane AntigenOptimizing the management of high-risk, localized prostate cancerManagement of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directionsUnmet needs in the prediction and detection of metastases in prostate cancer.A prostate-specific antigen doubling time of <6 months is prognostic for metastasis and prostate cancer-specific death for patients receiving salvage radiation therapy post radical prostatectomy.Use of androgen deprivation therapy in prostate cancer: indications and prevalence.The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy.Impact of treatment on progression to castration-resistance, metastases, and death in men with localized high-grade prostate cancer.The effect of the frequency and duration of PSA measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer.Current status of immunological therapies for prostate cancer.(2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted α-Particle Radiopharmaceutical Therapy.Current status of immunological approaches for the treatment of prostate cancerSipuleucel-T for the treatment of metastatic prostate cancer: promise and challenges.Targeting angiogenesis for the treatment of prostate cancer.Current mouse and cell models in prostate cancer research.The utility of prostate-specific antigen in the management of advanced prostate cancer.Interobserver variability in the pathological assessment of radical prostatectomy specimens: findings of the Laparoscopic Prostatectomy Robot Open (LAPPRO) study.PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance.Natural history of untreated prostate specific antigen radiorecurrent prostate cancer in men with favorable prognostic indicators.Imaging biomarkers in prostate cancer: role of PET/CT and MRI.
P2860
Q26777128-7488A5BF-15EA-4017-9716-810396128C19Q26849220-2B2F1775-EB3D-4D21-ADE1-82D96DE582FFQ26851608-239DE0DF-FE09-4E87-BDE1-C0D2CD951390Q30009388-63AED036-6128-4A9A-9A70-C5A766307FD0Q30651147-E8F5736D-89E8-4EEB-81FD-6E149A6F7AFBQ33631383-364D7AA4-C6E5-4258-8F8F-622AB8D534E0Q34002312-55B3581F-1778-4A71-AB56-82745CF104F0Q34013808-82985709-3C14-4DEF-99F4-0227BEEBBEF4Q34208260-F83C3547-6EFA-4B4B-B024-210F26F0093AQ34372567-7929A993-C802-4D82-A93E-BADF2DEBAE02Q34514927-4345F886-B2CC-458F-868F-4CA85A4AE623Q35070443-B743D629-5FE9-4F74-A797-8F82F89FF7E7Q35096149-39441B91-FBFB-49D9-850E-CDE2BA5D598DQ35188264-60909B57-8098-48FB-A673-1376A9232174Q35470434-A5B8E848-EFCE-4D69-9201-5E335BF4CE35Q35641782-30958600-29BD-497F-A16C-5FBE7E58AB6DQ35656240-A8AD727B-3B72-4B99-A611-AE044EE7694EQ35827582-78200408-54A8-4B42-A5FA-5CCAB09D74CBQ36104473-239A5B19-ABC5-41A2-AE25-1B88FCAD4E98Q36199750-6A9C0BCB-84FB-4F4D-9793-14EC19D76F80Q36252485-1FF4204F-926D-430D-A131-838F07BDF159Q36492451-76CCA542-A784-4B9C-A5B1-3BCB68D46B39Q36760953-B39E1057-93F2-4BBC-A3AB-D2F6005E4BABQ36871680-D2282680-21BC-4FD2-B3A9-14F2195A3348Q37033549-7C73264E-F472-43F5-A925-9A42FB0AE159Q37074379-2DE99E6B-E1F3-4C11-BFFB-05B26D794F13Q37213044-A1C0F461-6E3A-4870-BE23-F6AFB90883C3Q37609253-7F6E6110-ED26-45BC-AC51-F850CA6B30F7Q37623774-CBD9282F-856F-457F-ACCA-CF0F4268530FQ37697477-C1A92B2C-20E2-46AB-90FB-3523B182FDC2Q37722429-4048AAC0-FE6D-4D53-937F-F685C226A8F1Q37983491-0E9CDC16-FFB8-4C53-ACC9-077D23B9B842Q37984189-AD330A8E-29A9-4A94-873B-8EEAC85EA3F8Q37993137-97F97913-5A32-4A47-9FEE-EE1C1BE8B000Q38098499-659FD3BA-7FBB-418B-B842-34030E5776E7Q38119260-D6FF5563-A8D8-4015-8CFD-C8782EAC35EFQ38125826-097156C1-8275-438C-A51B-EAC6F43191FCQ38206682-DF82172F-4CAC-4D39-8A02-2C1044F206E8Q38257845-D9FCDEC1-283F-451F-AD4A-12308DE8AD14Q38321182-523CB0A8-D6CA-407B-8BD7-515AA6EEA462
P2860
The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
The natural history of metasta ...... tatectomy: long-term follow-up
@en
type
label
The natural history of metasta ...... tatectomy: long-term follow-up
@en
prefLabel
The natural history of metasta ...... tatectomy: long-term follow-up
@en
P2093
P2860
P1433
P1476
The natural history of metasta ...... tatectomy: long-term follow-up
@en
P2093
Bruce J Trock
Elizabeth B Humphreys
Emmanuel S Antonarakis
Mario A Eisenberger
Michael A Carducci
Patrick C Walsh
Zhaoyong Feng
P2860
P356
10.1111/J.1464-410X.2011.10422.X
P577
2011-07-20T00:00:00Z